A new asymmetric synthetic route to (-)-galanthamine (1.01), a potent Amaryllidaceae alkaloid used in the symptomatic treatment of early on-set Alztheimer's disease (AD), was successfully developed with complete stereocontrol. Key to achieving high chemo-and stereo-selectivity in this approach was the use of transition metal (IM) mediated reactions, in the form of an enyne RCM; a Heck coupling and a titanium based asymmetric allylation. Additionally, application of an asymmetric imino-aldol reaction resulted in the short total synthesis of two Lupin-type alkaloids, tashiromine (3.01) and epilupinine (3.02).